In this work, the role of cardiac biomarkers measured from blood to predict cardiovascular events and death is tested in individuals of the general population and particularly in those with known diabetes. The work is based on a cooperation of different population studies across Europe and includes more than 90 000 individuals, with more than 6000 having diabetes. We could demonstrate that the determination of three cardiac biomarkers helps to identify individuals at highest risk for cardiovascular events (e.g. myocardial infarction or stroke) and death, despite accounting for known cardiovascular risk factors in these individuals. Therefore, these biomarkers should be considered for routine risk assessment for cardiovascular diseases and could improve the early identification of high-risk individuals, consequently leading to an earlier initiation of preventive therapies.

Biomarker-based prediction of fatal and non-fatal cardiovascular outcomes in individuals with diabetes mellitus

Iacoviello L.
Writing – Review & Editing
;
Costanzo S.;De Ponti R.
Writing – Review & Editing
;
Veronesi G.
Writing – Review & Editing
;
Ferrario M.
Writing – Review & Editing
;
2023-01-01

Abstract

In this work, the role of cardiac biomarkers measured from blood to predict cardiovascular events and death is tested in individuals of the general population and particularly in those with known diabetes. The work is based on a cooperation of different population studies across Europe and includes more than 90 000 individuals, with more than 6000 having diabetes. We could demonstrate that the determination of three cardiac biomarkers helps to identify individuals at highest risk for cardiovascular events (e.g. myocardial infarction or stroke) and death, despite accounting for known cardiovascular risk factors in these individuals. Therefore, these biomarkers should be considered for routine risk assessment for cardiovascular diseases and could improve the early identification of high-risk individuals, consequently leading to an earlier initiation of preventive therapies.
2023
2023
Biomarkers; Cardiovascular events; Diabetes; hs-CRP; hs-cTnI; NT-proBNP
Haller, P. M.; Gossling, A.; Magnussen, C.; Brenner, H.; Schottker, B.; Iacoviello, L.; Costanzo, S.; Kee, F.; Koenig, W.; Linneberg, A.; Sujana, C.; Thorand, B.; Salomaa, V.; Niiranen, T. J.; Soderberg, S.; Volzke, H.; Dorr, M.; Sans, S.; Padro, T.; Felix, S. B.; Nauck, M.; Petersmann, A.; Palmieri, L.; Donfrancesco, C.; De Ponti, R.; Veronesi, G.; Ferrario, M.; Kuulasmaa, K.; Zeller, T.; Ojeda, F. M.; Blankenberg, S.; Westermann, D.
File in questo prodotto:
File Dimensione Formato  
zwad122.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 1.63 MB
Formato Adobe PDF
1.63 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2158872
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact